Concentrix Falls, Jefferies Mixed, ImmunityBio Down as FDA Issues Warning Letter on Cancer Claims

Stock Movers

On this episode of Stock Movers:

-  Concentrix (CNXC) shares fall as the software company’s second-quarter forecast was weaker than expected. Vital Knowledge also notes “a modest shortfall on FQ1 EPS,” given margin compression.

- Jefferies (JEF) shares are mixed. Hedge fund founder George Weiss has lost his defamation suit accusing Jefferies Financial Group of running a “smear campaign” to pressure him to pay a $100 million debt owed by his firm, Weiss Multi-Strategy Advisers.

- ImmunityBio (IBRX) shares fell as much as 25%, the most intraday since 2024, after the FDA warned Anktiva ads are false and misleading, citing unapproved claims and regulatory violations. 

See omnystudio.com/listener for privacy information.

More description

On this episode of Stock Movers:

-  Concentrix (CNXC) shares fall as the software company’s second-quarter forecast was weaker than expected. Vital Knowledge also notes “a modest shortfall on FQ1 EPS,” given margin compression.

- Jefferies (JEF) shares are mixed. Hedge fund founder George Weiss has lost his defamation suit accusing Jefferies Financial Group of running a “smear campaign” to pressure him to pay a $100 million debt owed by his firm, Weiss Multi-Strategy Advisers.

- ImmunityBio (IBRX) shares fell as much as 25%, the most intraday since 2024, after the FDA warned Anktiva ads are false and misleading, citing unapproved claims and regulatory violations. 

See omnystudio.com/listener for privacy information.

2026-03-24 2 min Transcript
Listen elsewhere

Available Results

Generated results are saved to your library for reuse and search.

No generated results are available for this episode yet.

Transcript

Open the Transcript tab to load the transcript.

Chapters

No chapters available.